{"id":"intranasal-diclofenac-sodium","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasal irritation"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Gastrointestinal discomfort"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Diclofenac blocks both COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. The intranasal formulation delivers the drug directly to nasal mucosa for rapid systemic absorption, potentially providing faster onset of analgesia compared to oral formulations. This route of administration may also reduce gastrointestinal exposure and associated side effects.","oneSentence":"Intranasal diclofenac sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:41.014Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute pain management (likely indication based on intranasal NSAID development)"}]},"trialDetails":[{"nctId":"NCT06158620","phase":"PHASE1, PHASE2","title":"Intra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-03-01","conditions":"Post Operative Pain, Urolithiasis, Ureter Calculi","enrollment":80},{"nctId":"NCT06731556","phase":"PHASE3","title":"Analgesic Effects of Intranasal Diclofenac Sodium, Ibuprofen, and Paracetamol in Pediatric Tonsillectomy Cases","status":"COMPLETED","sponsor":"Bezmialem Vakif University","startDate":"2024-12-15","conditions":"Tonsil Disease, Pain Management, Intranasal Drug Administration","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Intranasal Diclofenac Sodium","genericName":"Intranasal Diclofenac Sodium","companyName":"Bezmialem Vakif University","companyId":"bezmialem-vakif-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intranasal diclofenac sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. Used for Acute pain management (likely indication based on intranasal NSAID development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}